Business

Merck posts full Phase 3 data for pulmonary arterial hypertension (NYSE:MRK)


Merck & Co's headquarters.  in Silicon Valley

Photography Magazine / iStock Editor via Getty Images

Merck (NYSE:A) closed ~4% higher on Monday, marking the largest single-day increase since June 2022 after the disclosure of complete Phase 3 results for the biologic sotatercept, which is targeted for the treatment of arterial hypertension pulmonary embolism (PAH) due to vascular disorders.

The

news7f

News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button